AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026230260
Cite this article
1
Download
4
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Exploratory analysis of CT-derived radiomic features and adipose tissue distribution in relation to lipid metabolism pathway activity in ovarian serous cystadenocarcinoma

Federico Greco1* ,  Luca Giordano2 ,  Chiara Noemi Greco2 ,  Chiara Pallara3 ,  Luca Leo2 ,  Roberta Montefrancesco2 ,  Arnaldo Scardapane1
Show Less
1 Department of Experimental Medicine, College ISUFI, University of Salento, Monteroni, Lecce , Italy
2 Department of Radiology, “Vito Fazzi” Hospital, Lecce , Italy
3 Interdisciplinary Department of Medicine, Section of Radiology and Radiation Oncology, University of Bari “Aldo Moro”, Bari , Italy
Received: 6 June 2026 | Revised: 24 June 2026 | Accepted: 17 July 2026 | Published online: 16 November 2026
(This article belongs to the Special Issue Tumor Immune Microenvironment and Intervention Strategies)
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Introduction: Ovarian cancer is characterized by high recurrence rates and complex metabolic reprogramming. Lipid metabolism pathways may influence tumor imaging phenotypes and contribute to biologic heterogeneity.

Objective: This study investigated whether computed tomography (CT)-derived radiomic features are associated with metabolic activity profiles in ovarian cancer.

Methods: This retrospective radiogenomic study included 68 patients from the Cancer Genome Atlas Ovarian Cancer cohort with available contrast-enhanced CT imaging and matched transcriptomic data. Patients were stratified into high and low metabolic activity groups according to lipid metabolism-related pathway expression profiles. A two-dimensional radiomic approach was adopted using the axial CT slice showing the largest tumor area. Tumor regions were manually segmented, and handcrafted radiomic features were extracted using a custom pipeline developed in Python. Statistical comparisons between groups were performed using the Mann–Whitney U test with Benjamini–Hochberg false discovery rate (FDR) correction.

Results: Several radiomic features showed nominal or borderline differences between high- and low-metabolic-activity groups, including glcm_ASM_std (p = 0.027), shape_perimeter_mm (p = 0.045), glrlm_rln (p = 0.049), shape_minor_axis_length_px (p = 0.050), and intensity_p10_HU (p = 0.053). Tumors with higher metabolic activity tended to exhibit larger morphologic dimensions and subtle texture alterations. Subcutaneous adipose tissue (SAT) demonstrated the strongest inverse correlation with LipidScore (Spearman rho = −0.24), and a non-significant trend toward higher SAT values was observed in the low-lipid-metabolism group (p = 0.072). However, none of the radiomic features remained statistically significant after FDR correction.

Conclusion: CT-derived radiomic features showed weak exploratory associations with metabolic activity-related molecular profiles in ovarian cancer. Although no robust associations were confirmed after multiple-comparison correction, the observed trends suggest potential radiogenomic interactions related to tumor metabolism that warrant further investigation in larger cohorts.

Keywords
Adipose tissue
Lipid metabolism
Ovarian serous cystadenocarcinoma
Radiogenomics
Radiomics
Funding
None.
Conflict of interest
The authors declare no conflicts of interest to report regarding the present study.
References
  1. Ji Z, Shen Y, Feng X, et al. Deregulation of lipid metabolism: the critical factors in ovarian cancer. Front Oncol. 2020;10:593017. doi: 10.3389/fonc.2020.593017
  2. Chaudhry S, Thomas SN, Simmons GE Jr. Targeting lipid metabolism in the treatment of ovarian cancer. Oncotarget. 2022;13(1):768-783. doi: 10.18632/oncotarget.28241
  3. Jiang L, Fang X, Wang H, Li D, Wang X. Ovarian cancer-intrinsic fatty acid synthase prevents anti-tumor immunity by disrupting tumor-infiltrating dendritic cells. Front Immunol. 2018;9:2927. doi: 10.3389/fimmu.2018.02927
  4. Li J, Condello S, Thomes-Pepin J, et al. Lipid desaturation is a metabolic marker and therapeutic target of ovarian cancer stem cells. Cell Stem Cell. 2017;20(3):303-314.e5. doi: 10.1016/j.stem.2016.11.004
  5. Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5(1):e189. doi: 10.1038/oncsis.2015.49
  6. Zhao S, Cheng L, Shi Y, Li J, Yun Q, Yang H. MIEF2 reprograms lipid metabolism to drive progression of ovarian cancer through ROS/AKT/mTOR signaling pathway. Cell Death Dis. 2021;12(1):18. doi: 10.1038/s41419-020-03336-6
  7. Zhang Q, Zhou W, Yu S, et al. Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation. Oncogene. 2021;40(1):97-111. doi: 10.1038/s41388-020-01516-4
  8. Ma Y, Temkin SM, Hawkridge AM, et al. Fatty acid oxidation: an emerging facet of metabolic transformation in cancer. Cancer Lett. 2018;435:92-100. doi: 10.1016/j.canlet.2018.08.006
  9. Meier A, Veeraraghavan H, Nougaret S, et al. Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer. Abdom Radiol (NY). 2019;44(6):2040-2047. doi: 10.1007/s00261-018-1840-5
  10. Vargas HA, Veeraraghavan H, Micco M, et al. A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. Eur Radiol. 2017;27(9):3991-4001. doi: 10.1007/s00330-017-4779-y
  11. Jian J, Li Y, Pickhardt PJ, et al. MR image-based radiomics to differentiate type I and type II epithelial ovarian cancers. Eur Radiol. 2021;31(1):403-410. doi: 10.1007/s00330-020-07091-2
  12. Li H, Cai S, Deng L, et al. Prediction of platinum resistance for advanced high-grade serous ovarian carcinoma using MRI-based radiomics nomogram. Eur Radiol. 2023;33(8):5298-5308. doi: 10.1007/s00330-023-09552-w
  13. Holback C, Jarosz R, Prior F, et al. The Cancer Genome Atlas Ovarian Cancer Collection (TCGA-OV). Published online 2016. doi: 10.7937/K9/TCIA.2016.NDO1MDFQ
  14. Noumura Y, Kamishima T, Sutherland K, Nishimura H. Visceral adipose tissue area measurement at a single level: can it represent visceral adipose tissue volume? Br J Radiol. 2017;90(1077):20170253. doi: 10.1259/bjr.20170253
  15. Greco F, Panunzio A, Bernetti C, Tafuri A, Beomonte Zobel B, Mallio CA. Exploring the ADAM12 expression in clear cell renal cell carcinoma: a radiogenomic analysis on CT imaging. Acad Radiol. 2024;31(9):3672-3677. doi: 10.1016/j.acra.2024.02.032
  16. Liu Z, Duan T, Zhang Y, et al. Radiogenomics: a key component of precision cancer medicine. Br J Cancer. 2023;129(5):741-753.
  17. Song L, Zhu Z, Mao L, et al. Clinical, conventional CT and radiomic feature-based machine learning models for predicting ALK rearrangement status in lung adenocarcinoma patients. Front Oncol. 2020;10:369. doi: 10.3389/fonc.2020.00369
  18. Peeken JC, Bernhofer M, Wiestler B, et al. Radiomics in radiooncology—challenging the medical physicist. Phys Med. 2018;48:27-36. doi: 10.1016/j.ejmp.2018.03.012
  19. Zeng S, Wang XL, Yang H. Radiomics and radiogenomics: extracting more information from medical images for the diagnosis and prognostic prediction of ovarian cancer. Mil Med Res. 2024;11(1). doi: 10.1186/s40779-024-00580-1
  20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013
  21. Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev. 2019;99(4):1819-1875. doi: 10.1152/physrev.00035.2018
  22. Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669-680. doi: 10.1038/s41568-021-00378-6
  23. Corn KC, Windham MA, Rafat M. Lipids in the tumor microenvironment: from cancer progression to treatment. Prog Lipid Res. 2020;80:101055. doi: 10.1016/j.plipres.2020.101055
  24. Calder PC. Functional roles of fatty acids and their effects on human health. JPEN J Parenter Enteral Nutr. 2015;39(1 suppl):18S-32S. doi: 10.1177/0148607115595980
  25. Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121-135. doi: 10.1016/j.metabol.2018.11.001
  26. Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Annu Rev Med. 2015;66(1):297-309. doi: 10.1146/annurev-med-050913-022228
  27. Brown KA, Scherer PE. Update on adipose tissue and cancer. Endocr Rev. 2023;44(6):961-974. doi: 10.1210/endrev/bnad015
  28. Vona-Davis L, Rose DP. The obesity-inflammation-eicosanoid axis in breast cancer. J Mammary Gland Biol Neoplasia. 2013;18(3-4):291-307. doi: 10.1007/s10911-013-9299-z
  29. Kolb H. Obese visceral fat tissue inflammation: from protective to detrimental? BMC Med. 2022;20(1):494. doi: 10.1186/s12916-022-02672-y
  30. Sah S, Bifarin OO, Moore SG, et al. Serum lipidome profiling reveals a distinct signature of ovarian cancer in Korean women. Cancer Epidemiol Biomarkers Prev. 2024;33(5):681-693. doi: 10.1158/1055-9965.EPI-23-1293
  31. Li Y, Shang C, Liang H, Zhang K, Wu Y, Guo H. Associations of novel serum lipid index with epithelial ovarian cancer chemoresistance and prognosis. Front Oncol. 2023;13:1052760. doi: 10.3389/fonc.2023.1052760
  32. Zhong X, Bilal M, Zhou Y, et al. Elucidating the role of fatty acid reprogramming in ovarian cancer: insights cross-talk between blood, subcutaneous fat, and ovarian cancer tissues. Front Oncol. 2025;15:1530487. doi: 10.3389/fonc.2025.1530487
  33. Matuszczak M, Kiljańczyk A, Marciniak W, et al. Blood molybdenum level as a marker of cancer risk on BRCA1 carriers. Hered Cancer Clin Pract. 2024;22(1). doi: 10.1186/s13053-024-00291-7
  34. Wen Z, Liu H, Li M, et al. Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration. Oncogene. 2015;34(10):1241-1252. doi: 10.1038/onc.2014.85
  35. Rocconi RP, Kirby TO, Seitz RS, et al. Lipoxygenase pathway receptor expression in ovarian cancer. Reprod Sci. 2008;15(3):321-326. doi: 10.1177/1933719108316390
  36. Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacol Rep. 2010;62(2):233-244. doi: 10.1016/S1734-1140(10)70262-0
  37. Gu P, Su Y, Guo S, et al. Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Invest. 2008;26(8):822-829. doi: 10.1080/07357900801941860
  38. Wang YP, Wang QY, Li CH, Li XW. COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. Chem Biol Interact. 2018;292:24-29. doi: 10.1016/j.cbi.2018.06.020
  39. Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25(5-6):495-520. doi: 10.1016/j.mam.2004.06.004
  40. Shao H, Mohamed EM, Xu GG, et al. Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget. 2016;7(4):3832-3846. doi: 10.18632/oncotarget.6757
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing